Riset publik selama kuartal pertama mencapai lebih dari 10.000 kali, saham terkait "Spesialisasi, Keunggulan, dan Inovasi" paling disukai

Reporter Peng Yansong

This quarter (Q1), the A-share market is nurturing structural opportunities amid volatility, and public fund institutions are accelerating their on-site research pace. According to data from the Public Fund Pai Pai Net, as of March 31, in Q1 there were 160 public fund institutions participating in research on A-share listed companies. They covered 894 individual stocks across 30 industries including electronic and mechanical equipment, and the total number of research visits reached 10054 times. In terms of research focus, institutions showed greater attention to stocks related to “specialized, refined, distinctive, and innovative” enterprises, indicating that the investment mainline for the whole year of 2026 may revolve around industrial upgrading and self-reliance.

Looking at individual stocks, in Q1 the top ten stocks by the number of research visits by public fund institutions were all researched no fewer than 67 times. Da Jin Heavy Industry in the power equipment industry topped the list with 115 research visits, becoming the only stock with more than 100 research visits. In addition, Jingzhida and Naipu Mining Machinery in the mechanical equipment sector, Silingzhi Drive and Chaore Shares in the automotive industry, and Aipeng Medical and BeiGene China in the pharmaceutical and biological industry were also widely watched by public fund institutions.

Of note, in Q1 public fund institutions’ attention to stocks related to “specialized, refined, distinctive, and innovative” enterprises increased significantly. Among the top ten stocks by research visit counts in Q1, there were 7 stocks related to “specialized, refined, distinctive, and innovative” enterprises: Jingzhida, Silingzhi Drive, Haitian Ruisheng, Aipeng Medical, Chaore Shares, Naipu Mining Machinery, and Aladdin. Overall, among the 894 individual stocks researched by public fund institutions in Q1, there were 261 stocks related to “specialized, refined, distinctive, and innovative” enterprises, accounting for 29.19% of the total number of researched stocks.

From an industry perspective, three major industries—electronic, mechanical equipment, and pharmaceutical and biological—were especially favored by public funds. Whether measured by the number of stocks researched or by research visit counts, they clearly led.

More specifically, the electronic industry ranked first with 1848 research visits and coverage of 141 stocks. Stocks such as Dongxin Co., Ltd., Juchen Holdings, InnoSilicon, Bera Storage, Shen gong Co., Ltd., and Aobei Zhongguang were also researched more than 40 times each, showing institutions’ continued attention to sub-sectors such as storage and optical sensing. The mechanical equipment industry ranked second with 1258 research visits and coverage of 112 stocks. Institutions focused on technological upgrades and order market conditions in areas such as high-end equipment, industrial mother machines, and mining machinery. The pharmaceutical and biological industry followed closely with 1256 research visits and coverage of 84 stocks; Aipeng Medical, Xiangyu Medical, Xishan Technology, and Frontier Biotech became key focus areas for public fund institutions.

Zhang Quan, fund manager at Xcai Fund, told reporters from Securities Daily that in 2026, continued overseas licensing (License—out) transactions will remain an important engine for sustained upward momentum in the innovative drug sector. As the sector’s overall valuation has been repaired last year, in the future innovative drug investing will place greater emphasis on stock selection and the quality of industry tracks; frontier technology directions such as ADC (antibody-drug conjugates), bispecific antibodies (dual-specific antibodies), and small nucleic acid drugs are set to become key highlights.

In addition, in Q1, sectors such as power equipment, computers, and automobiles also received strong attention from public fund institutions, with research visit counts all exceeding 400 times.

From the perspective of research institutions, in Q1 the top ten public fund institutions by research visit counts all completed no fewer than 161 research visits. Among them, Boshi Fund became the “most diligent” institution in Q1 with 275 research visits, and received intensive attention on Huarui Precision, Aladdin, Haitian Ruisheng. Huaxia Fund came next with 229 research visits, focusing on targets such as Chaore Shares, Aladdin, China Resources Micro, Puris, and Xiangpiaopiao. In Q1, Fuguo Fund, E Fund, and Jiamshi Fund all had no fewer than 200 research visits, demonstrating continuous investment by leading institutions in investment research and development.

(Editor: Wen Jing)

Keywords:

                                                            Fund
                                                            Public offering